ANTI-IDO1 CLONE 1B17 ZOOMAB RABBIT MONOCLONAL (C15-1670-707)

General description

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Specificity

Clone 1B17 is a ZooMAb^® rabbit recombinant monoclonal antibody that specifically detects Indoleamine 2,3-dioxygenase 1 (IDO1). It targets an epitope within 24 amino acids from the C-terminal region.

Immunogen

KLH-conjugated linear peptide corresponding to 24 amino acids from the C-terminal region of human Indoleamine 2,3-dioxygenase 1 (IDO1).

Application

Quality Control Testing

Evaluated by Western Blotting in lysate from HeLa cells treated with Interferon .

Western Blotting Analysis (WB): A 1:1,000 dilution of this antibody detected IDO1 in lysate from HeLa cells treated with Interferon (100 ng/mL; 24h), but not in lysates from untreated cells.

Tested applications

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected IDO1 in overnight serum starved HeLa cells treated with IFN- (100 ng/mL; 24 h).

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected IDO1 in human tonsil tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Evaluated by Western Blotting in lysate from HeLa cells treated with Interferon .

Western Blotting Analysis (WB): A 1:1,000 dilution of this antibody detected IDO1 in lysate from HeLa cells treated with Interferon (100 ng/mL; 24h), but not in lysates from untreated cells.

Target description

Indoleamine 2,3-dioxygenase 1 (UniProt: P14902; also known as EC:1.13.11.52, IDO-1, Indoleamine-pyrrole 2,3-dioxygenase) is encoded by the IDO1 (also known as IDO, INDO) gene (Gene ID: 3620) in human. IDO1 is a heme containing cytosolic enzyme that catalyzes the rate-limiting step in tryptophan catabolism to N-formyl-kynurenine by cleaving the 2,3-double bond of the indole ring while a molecular oxygen merges into the unsealed molecule. The reduction in local tryptophan and the upregulated immunomodulatory tryptophan metabolites form the basis of IDO-dependent regulation of inflammation and immunity. It is expressed by a wide variety of tissues and its levels can be upregulated by interferon- . It is reported to support carcinogenesis by modulating tissue microenvironment inflammatory responses and mediates immune escape in cancer by suppressing the function of T effector cells and promote the differentiation of T regulatory cells. Overexpression of IDO1 is also associated with poor prognosis in various cancers. IDO-1 can limit the growth of intracellular pathogens by depriving them of tryptophan. This ZooMAbZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Tang, K., et al.(2021). J. Hematol. Oncol. 14; Article 68; Baren, NV., and Van den Eynde, BJ. (2015). Front. Immunol. 6; 34).

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

Reconstitution

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.